Navigation Links
BioMarin to Host Second Quarter 2009 Financial Results Conference Call and Webcast on Thursday, July 30 at 5:00 p.m. ET (23:00 CET)
Date:7/1/2009

NOVATO, Calif., July 1 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, July 30, at 5:00 p.m. ET (23:00 CET) to discuss second quarter 2009 financial results.

    U.S. / Canada Dial-in Number:  866.272.9941
    International Dial-in Number:  617.213.8895
    Participant Code: 45596036
    Replay Dial-in Number: 888.286.8010
    Replay International Dial-in Number: 617.801.6888
    Replay Code: 74141589

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is in clinical development for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase 1/2 clinical development for the treatment of MPS IVA. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin(R), Naglazyme(R) and Kuvan(R) are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

    Contacts:

    Investors                               Media
    Eugenia Shen                            Susan Berg
    BioMarin Pharmaceutical Inc.            BioMarin Pharmaceutical Inc.
    (415) 506-6570                          (415) 506-6594


'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. BioMarin to Present at the Bear Stearns 20th Annual Healthcare Conference
2. BioMarin Provides Grant to NORD to Expand PKU Patient Support Services
3. BioMarin Re-Acquires Rights to Kuvan in Canada From Merck Serono
4. Fairview Specialty Pharmacy Signs Contract With BioMarin for Distribution of Kuvan(TM)
5. BioMarin to Host Fourth Quarter and Full Year 2007 Financial Results Conference Call and Webcast on Tuesday, February 26 at 5:00 p.m. ET (23:00 CET)
6. BioMarin to Present at the Cowen and Company 28th Annual Healthcare Conference
7. BioMarin to Present at the Lehman Brothers Global Healthcare Conference
8. BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome
9. BioMarin and La Jolla Pharmaceutical Sign Worldwide (Excluding Asia Pacific) Development and Commercialization Agreement for Riquent
10. BioMarin to Present at the 27th Annual J.P. Morgan Healthcare Conference
11. BioMarin Supports Observance of Rare Disease Day February 28
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... February 13, 2016 , ... Good ... the first in the area to offer AngioPlex™ Optical Coherence Tomography (OCT) Angiography, ... such as macular degeneration, diabetic retinopathy, and other vascular conditions. , In just ...
(Date:2/13/2016)... ... , ... Hidden Cypress in Sun City is the place to be on March 3rd to ... Weniger will be hosting this educational seminar from 5:30 p.m. – 7:00 p.m. Exciting ... pricing on offers. In addition, prizes will be given away and light refreshments will be ...
(Date:2/13/2016)... California (PRWEB) , ... February 13, 2016 , ... Valentine’s ... landing a date for the big day. A great outfit, flawless hair, and a ... they might as well resign themselves to a night at home with Rover. (Actually, ...
(Date:2/13/2016)... Washington, D.C. (PRWEB) , ... February 13, 2016 ... ... joined with Faces and Voices of Recovery, the leading national organization representing the ... paper urging candidates for public office to include Family Recovery in policies addressing ...
(Date:2/13/2016)... ... February 13, 2016 , ... Many individuals looking to lead a ... multitude of reasons. IsoPasta by Isolator Fitness has delved into this niche allowing ... without the high-carb repercussions. IsoPasta has 30 grams of protein and only 7 ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... The primary goal of this research is ... the usage of liquid biopsy. Key information the survey ... Timeframe of liquid biopsy adoption amidst future users - ... type - Sample inflow to conduct liquid biopsy tests ... and so on. - Correlation analysis of sample type ...
(Date:2/11/2016)... Laboratory glassware and plasticware include ... may range from microscope slides to large storage boxes ... borosilicate glass because of its low weight and resistance ... started gaining popularity over the past decade when it ... with plastic in several applications due to its resistance ...
(Date:2/11/2016)... 2016  Governor Andrew M. Cuomo today announced a ... throughout Western New York . This ... Polytechnic Institute, includes a major expansion of Athenex,s North ... Buffalo , as well as the creation of ... Dunkirk . The combined projects are expected ...
Breaking Medicine Technology: